Background High-risk (HR) human papillomavirus (HPV) infection is an established cause of
malignant disease. We used a societal perspective to estimate the cost of HR HPV-related …

Objective: A transmission dynamic model was used to assess the epidemiological and
economic impact of a quadrivalent human papillomavirus (HPV)(6/11/16/18) vaccine in …

With the availability of new patient-applied treatments for genital and perianal warts, medical
providers, physician groups, and health systems are reassessing the role of physician …

Objectives: One of the two new human papillomavirus (HPV) vaccines protects against HPV
types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV …

Genital warts, 90% of which are caused by human papillomavirus types 6 and 11, are a
significant problem in the UK. The cost of managing genital warts was previously estimated …

Objectives To obtain health-related quality of life valuations (ie, utilities) for human
papillomavirus (HPV)-related cancer health states of vulval, vaginal, penile, anal and …

Objectives: To determine the average cost of a case of genital warts, for both males and
females, with a view to informing the current debate as to which Human papillomavirus …

Background: This commentary discusses key issues for health economic evaluation and
modelling, applied to human papillomavirus (HPV) vaccine programs. Methods: We outline …

BACKGROUND: The economic evaluation of any human papillomavirus (HPV) vaccination
strategy requires the measurement of clinical benefits (quality-adjusted life-years [QALY]) …

Background Human papillomavirus (HPV) has proven to be the cause of several severe
clinical conditions on the cervix, vulva, vagina, anus, oropharynx and penis. Several studies …